PROSTATE SPECIFIC ANTIGEN

French exceptionalism

Holmström and colleagues confirm that no single cut-off value for prostate specific antigen concentration attained likelihood ratios formally required for a screening test. However, the number of men who would need to be offered screening to prevent one death from prostate cancer during a 10 year period is not 1068 but 14:10. Everywhere, practice guidelines are up to date and clearly cite the unproved benefit of screening for prostate specific antigen, as well as the adverse effects (high risk of overdiagnosis and overtreatment). Everywhere, that is, but in France. For the fifth consecutive year, French urologists are actively promoting prostate cancer screening, despite the arguments.

Alain Braillon, doctor, Public Health, University Hospitals, 80000 Amiens, France braillon.alain@chru-amiens.fr
Competing interests: None declared.

2 Bayly ML. Screening for prostate cancer—the controversy that refuses to die, NEngl JMed 2009;360:1351-4.